Dr. Max Pharma, the private label manufacturer of Dr. Max Group, reports a remarkable performance update for the year 2023. The own brand producer reinforces its position as a leading player in pharmaceutical manufacturing, evidenced by an outstanding 34 % growth in revenue compared to the previous year, across all six markets.

Since its launch in 2011, Dr. Max Pharma has emerged as a key subsidiary within the Dr. Max group, demonstrating consistent growth and expansion. In 2023, the contribution of the drug manufacturer to the group’s EBITDA  exceeded 40 %, underscoring its significant role in enhancing Dr. Max’s overall profitability.

Novelties-wise, Dr. Max Pharma expanded its own brand portfolio by introducing 119 new non-medicinal products in 2023. Additionally, amidst evolving regulatory and legislative landscapes, the company prioritized portfolio maintenance, ensuring compliance across different markets. The year also marks a robust growth in Gx (Unbranded Generics) department, with the introduction of 11 new Gx molecules translating to 47 prescription drugs SKUs (Stock Keeping Units). Presently, the subsidiary manages portfolio of  nearly 300 drug registrations, while reaching a total of around 1,300 SKUs for both medicines and non-medicines. These accomplishments celebrate Dr. Max Pharma becoming the largest pharmaceutical producer in the Czech Republic.

Beyond an outstanding annual performance result, Dr. Max Pharma also focused on enhancing the marketing support within the group in 2023. Focused efforts were directed towards standardizing product images and enhancing content creation across the portfolio, setting the stage for continued growth in 2024.

The announcement also highlights the remarkable achievement of selling 84 million products across Dr. Max pharmacies in various markets in 2023, a testament to the collaborative efforts of the group’s cross-functional teams. Dr. Max Pharma remains committed to steady growth in 2024, with a steadfast focus on affordability and accessibility.